Elevance Health (ELV) Earnings Date & Reports

Key Takeaways

• Adjusted diluted earnings per share (EPS) came in at $6.99, well above the roughly $4.70 consensus estimate.
• Operating revenue reached $50.4 billion, up 0.7% year over year and ahead of the approximately $49.3 billion analyst forecast.
• Management raised full-year 2026 adjusted EPS guidance to at least $29, up from the prior outlook of at least $27.
• The benefit expense ratio improved 70 basis points to 90.6%, reflecting better performance in Medicare Advantage and individual Affordable Care Act (ACA) plans.
• Medical membership fell to about 44.9 million, down 487,000 from a year earlier, as growth in commercial fee-based plans partially offset Medicaid and Medicare declines.

Earnings Context and Why It Matters

Elevance Health's third quarter results arrive at a pivotal moment for the managed-care sector. Investors have been closely watching how major insurers manage medical costs across their Medicaid, Medicare Advantage, and individual ACA books, as elevated care utilization and shifting rate environments have pressured margins across the industry. For Elevance, the report also serves as a test of its diversified model, which pairs its Health Benefits insurance operations with the Carelon services platform. A strong beat combined with raised guidance signals improving cost discipline and execution, while the continued decline in membership highlights the balancing act between profitability and enrollment growth that will shape the company's trajectory into 2027.

Reported Results

For the third quarter ended September 30, 2026, Elevance Health reported adjusted diluted EPS of $6.99, far exceeding the consensus estimate of approximately $4.70. Operating revenue rose 0.7% year over year to $50.4 billion, topping the roughly $49.3 billion analysts expected. On a GAAP (Generally Accepted Accounting Principles) basis, net income increased to $1.34 billion, or $6.27 per diluted share, compared with $1.19 billion, or $5.32 per share, in the prior-year period.

The closely watched benefit expense ratio, which compares medical costs to premium revenue, improved 70 basis points to 90.6%. The company attributed the improvement to better performance in Medicare Advantage and individual ACA plans, as well as favorable Medicaid rate actions. The Health Benefits segment generated operating revenue of $43.4 billion, while the Carelon segment reported revenue of $19.3 billion, up 5%, with operating gain rising 17% to $0.9 billion.

Elevance raised its full-year 2026 adjusted EPS guidance to at least $29, and increased its operating cash flow outlook to at least $6.5 billion. The company also declared a fourth-quarter dividend of $1.72 per share.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking healthcare names like Elevance Health and broader insurance-sector movers, the AI Screener offers a structured way to surface potential opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

The market responded favorably to the results. Shares of Elevance Health rose following the announcement, with the stock trading higher in the session as investors digested the earnings beat, the improved benefit expense ratio, and the upwardly revised guidance. The magnitude of the adjusted EPS beat, driven in part by roughly $1.85 per share of net non-operating benefit related to investment income valuation adjustments, gave the print an especially strong headline. Sentiment was further supported by management's confidence in delivering at least 12% adjusted EPS growth in 2027 from a higher earnings baseline of at least $26.75. Still, the ongoing decline in medical membership remains a point of focus for investors weighing near-term margin gains against longer-term enrollment momentum.

Forward Outlook and Key Factors to Monitor

Elevance enters the fourth quarter and 2027 with raised expectations and a clearer earnings path. Management now sees full-year 2026 adjusted EPS of at least $29 and reiterated confidence in at least 12% adjusted EPS growth in 2027, supported by margin improvement in Health Benefits, ongoing expansion of Carelon, and greater operating efficiency across the enterprise.

Several factors will shape whether the company can sustain this momentum. First, investors should watch Medicaid cost trends and rate alignment, which management views as stabilizing, with 2026 expected to mark the trough for Medicaid margins. Second, Medicare Advantage positioning for the 2027 annual enrollment period, including a focus on HMO (Health Maintenance Organization) plans and dual-eligible members, will be important for both margin and membership recovery. Third, the individual ACA business is expected to end the year with at least 1.2 million members, and sustained favorable claims development will be key to meeting the strengthened outlook.

Finally, the adjusted operating expense ratio rose 90 basis points to 11.3% as the company made targeted investments in member experience, medical cost management, and Carelon's value-based solutions. Whether those investments translate into durable efficiency gains and sustained membership growth will be central to the company's long-term earnings trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations